Director, National Field Access (Central)

The Director, National Field Access (Central) is a high-impact leadership role based in the United States. This position combines strategic leadership, operational execution, and hands-on problem solving to ensure patients receive timely access to critical therapies.

Requirements

• Bachelor’s degree required; advanced degree such as MBA, MPH, PharmD, or similar preferred.
• 12+ years of experience in pharmaceutical, biotechnology, healthcare, reimbursement, or market access roles.
• At least 5 years of direct leadership experience managing field-based teams such as Field Reimbursement Managers, Access Specialists, or related patient access professionals.
• Experience working within complex therapeutic areas such as rare disease, endocrinology, specialty medicine, or other high-touch access environments preferred.
• Strong knowledge of the U.S. payer and reimbursement landscape, including prior authorization processes, appeals, specialty pharmacy models, HUB operations, and patient support programs.
• Experience supporting product launches or post-launch access initiatives.
• Demonstrated ability to drive performance through teams, influence cross-functional stakeholders, and resolve complex business challenges.
• Strong analytical mindset with the ability to interpret data, identify trends, and convert insights into actionable strategies.
• Excellent communication, leadership, collaboration, and interpersonal skills.
• Ability to travel extensively within the assigned region, up to 60%, for field engagement and team support.

Benefits

• Competitive salary range of $191,100 to $253,900, with final compensation based on experience, skills, qualifications, and location.
• Comprehensive benefits package.
• Remote work flexibility.
• Opportunity to lead impactful patient access initiatives within a growing healthcare organization.
• Leadership role with significant visibility and influence across commercial and operational teams.
• Opportunity to contribute to improving access to innovative therapies for patients with serious medical needs.